Results 1 to 10 of about 105,026 (290)

Idiopathic pulmonary fibrosis: current diagnosis and treatment [PDF]

Jornal Brasileiro de Pneumologia, 2023
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront of new diagnostic algorithms and treatment developments that led to a shift in patients’ care in the past decade ...
Alexandre Franco Amaral, Philippe de Figueiredo Braga Colares, Ronaldo Adib Kairalla   +2 more
doaj   +1 more source

Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis

Scientific Reports, 2023
Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic interstitial pneumonia, characterized by chronic, progressive, and low survival rates, while unknown disease etiology.
Zenan Wu, Huan Chen, Shiwen Ke, Lisha Mo, Mingliang Qiu, Guoshuang Zhu, Wei Zhu, Liangji Liu   +7 more
doaj   +1 more source

IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.

PLoS ONE, 2021
Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow.
Yu Nakanishi, Yasushi Horimasu, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Takeshi Masuda, Taku Nakashima, Shintaro Miyamoto, Hiroshi Iwamoto, Shinichiro Ohshimo, Kazunori Fujitaka, Hironobu Hamada, Noboru Hattori   +11 more
doaj   +1 more source

Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break

Frontiers in Medicine, 2022
Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of ...
Paraskevi Kirgou, Sotirios I. Sinis, Ilias E. Dimeas, Ilias C. Papanikolaou, Konstantinos Tatsis, Athena Gogali, Konstantinos I. Gourgoulianis, Dimitrios P. Bogdanos, Zoe Daniil   +8 more
doaj   +1 more source

Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database

Pulmonary Circulation, 2021
The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan, Scott D. Barnett, Christopher S. King, Steeve Provencher, Joan A. Barbera, Jean Pastre, Oksana A. Shlobin, Werner Seeger   +7 more
doaj   +1 more source

The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis

Antioxidants, 2022
The mortality rate of idiopathic pulmonary fibrosis (IPF) increases yearly due to ineffective treatment. Given that the lung is exposed to the external environment, it is likely that oxidative stress, especially the stimulation of DNA, would be of ...
Jiahui Zhu, Lexin Liu, Xiaodi Ma, Xinyu Cao, Yu Chen, Xiangping Qu, Ming Ji, Huijun Liu, Chi Liu, Xiaoqun Qin, Yang Xiang   +10 more
doaj   +1 more source

Radiological findings based comparison of functional status in patients who have post-covid lung injury or idiopathic pulmonary fibrosis

BMC Pulmonary Medicine, 2023
Background Following COVID-19 infection, some patients acquired lung injury and fibrosis. Idiopathic pulmonary fibrosis is characterized by lung fibrosis.
Deniz Kızılırmak, Seçil Sarı, Fatma Can, Yavuz Havlucu   +3 more
doaj   +1 more source

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial [PDF]

, 2020
Compelling data have linked disease progression in patients with idiopathic pulmonary fibrosis (IPF) with lung dysbiosis and the resulting dysregulated local and systemic immune response.
A Mishra, AW Brown, B Ley, BA Karimi-Shah, BT Baxter, CJ Ryerson, DG Pankratz, DJ Lederer, G Raghu, G Raghu, H Scheper, HR Collard, J Andrade, J Coast, J Coast, K Loudon, K Loudon, KA Getz, KD Brandt, KE Thorpe, KF Schulz, L Richeldi, L Shulgina, LB Krupp, M Fralick, M Hammond, MA Fischl, MA Perazella, MO Paterniti, MT Durheim, P Bhattacharyya, PL Molyneaux, PL Molyneaux, PL Molyneaux, R Dal-Ré, RM Califf, RM du Bois, SD Nathan, SS Birring, T Katsuyama, TE King Jr, VA Varney, WS Jones, Y Huang   +43 more
core   +1 more source

Machine learning identified MDK score has prognostic value for idiopathic pulmonary fibrosis based on integrated bulk and single cell expression data

Frontiers in Genetics, 2023
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease that poses a significant challenge to medical professionals due to its increasing incidence and prevalence coupled with the limited understanding of its underlying molecular ...
Shichen Zhang, Lanlan Zhang, Lu Wang, Hongqiu Wang, Jiaxin Wu, Haoyang Cai, Chunheng Mo, Jian Yang   +7 more
doaj   +1 more source

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. [PDF]

, 2017
Idiopathic pulmonary fibrosis (IPF), a fibrosing interstitial pneumonia of unknown etiology, primarily affects older adults and leads to a progressive decline in lung function and quality of life.
Collard, Harold R, Oldham, Justin M
core   +2 more sources